WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that Aphios and its university collaborator Boston University Medical School were awarded a Phase I Small Business Technology Transfer Grant (STTR) from the National Cancer Institute (NCI) to develop a novel, nontoxic Vitamin D analog for hormone-refractory prostate cancer.
